search
Back to results

Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

Primary Purpose

Fatigue

Status
Withdrawn
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
IQP-AS-121
Sponsored by
InQpharm Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fatigue

Eligibility Criteria

21 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Caucasian males and females, 21-55 years of age
  2. Body mass index (BMI) 18.5-29.9 kg/m2
  3. Generally in good health without clinically significant findings at screening
  4. No chronic fatigue syndrome according to the Fukuda Centres for Disease Control and Prevention (CDC) criteria at screening
  5. Subjective feeling of chronic stress and tiredness for 3-12 last months prior to screening
  6. Screening Scale of Chronic Stress (SSCS) score >18
  7. Fatigue Severity Scale score >4
  8. ≤ 3 cups/portions of coffee and/or caffeine-containing food/beverages per day in the 3 last months prior to screening and during the study
  9. Regular stable continuous level of daily activities
  10. Regular sleep-wake cycle
  11. Normal dietary habits according to investigator's judgement
  12. ≤ moderate level of physical exercise
  13. Readiness to comply with study procedures, in particular:

    • Consumption of the IP during the treatment period
    • Filling in all questionnaires
    • Keep habitual diet and level of physical exercise
  14. No change in smoking habits during the study
  15. Women of child-bearing potential only:

    1. negative pregnancy testing (ß-HCG in urine at screening)
    2. commitment to use reliable contraception methods during the entire study Participation is based upon written informed consent form (ICF) by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Exclusion Criteria:

  1. Known sensitivity to any components of the IP
  2. Any medical condition associated with tiredness (e.g. iron deficiency, hypotension etc.)
  3. History and/or presence of clinically significant disease, which per investigator's judgement could interfere with the results of the study or the safety of the subject:

    1. Psychiatric diseases, e.g. depression, schizophrenia
    2. Eating disorders such as anorexia
    3. Untreated or non-stabilized metabolic diseases, e.g. diabetes mellitus
    4. Untreated or non-stabilized thyroid disorder
    5. Untreated or non-stabilized hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)
    6. Significant gastrointestinal diseases
    7. Insomnia
    8. Known bleeding disorders such as haemophilia
    9. Any other known significant or serious condition / disease that renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to screening, any clinically significant cardiovascular, renal, liver disease etc.)
  4. Use of medication which in the investigator's judgement could interfere with the results of the study (e.g. psychoactive medication, statins, proton pump inhibitors, blood-pressure medications, antihistamines, antibiotics, diuretics) within the last 4 weeks prior to screening and during the study
  5. Consumption of vitamins, nutritional supplements, supplementary balanced diet, mineral products which in the investigator's judgement could interfere with the results of the study within last 4 weeks prior to screening and during the study
  6. Consumption of adaptogens (e.g. ginseng or Schisandra) or St. John's Wort within last 4 weeks prior to screening and during the study
  7. Consumption of energy drinks during the study
  8. Start of use of contraception medication during the last 3 months prior to screening and during the study
  9. Use of anticoagulants such as warfarin
  10. Clinically significant deviation of laboratory parameters and/or deviations > 2 x ULN (upper limit of normal) at screening
  11. Recent or current significant stressors (e.g. active grieving)
  12. Chronic pain
  13. Chronic sleep deficiency (< 5 hours/night)
  14. Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
  15. Drug abuse
  16. Participation in another study during the last 30 days prior to screening
  17. Women of child-bearing potential: pregnant or breastfeeding
  18. Any situation expected during the study causing acute high level of stress
  19. Any other reason deemed suitable for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures

Sites / Locations

  • analyze & realize GmbH

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

IQP-AS-121

Arm Description

To be taken once daily dosing of 1 tablet in the morning.

Outcomes

Primary Outcome Measures

Change in VAS-F parameter
Compared between timepoints week 6 versus baseline - To assess fatigue and energy with 18 items which possesses two subscales: fatigue (13 items) and energy (5 items).

Secondary Outcome Measures

Change in Bond & Lader VAS parameter
Compared between timepoints week 6 versus baseline - To assess alertness, contentedness and calmness
Change in Number Connection Test
Compared between timepoints week 6 versus baseline - To assess visuo-spatial orientation and cognitive processing speed.
Change in FAIR-2
Compared between timepoints week 6 versus baseline - To measure attention as an ability to concentrate
Change in SF-12 parameter
Compared between timepoints week 6 versus baseline - To measure the overall health status of a subject
Change in PSQ20 parameter
Compared between timepoints week 6 versus baseline - Contained 30 items as an instrument to assess subjectively experienced stress
Change in POMS-35 parameters
Compared between timepoints week 6 versus baseline - The POMS-65 comprises 65 adjectives, separated into 6 subscales: 1) depression-dejection, 2) tension-anxiety, 3) anger-hostility, 4) confusion bewilderment, 5) fatigue-inertia and 6) vigour-activity.
Global evaluation of benefit
Assessed by the subjects and investigator at the end of study - To evaluate benefit of IP
Adverse events
Assessed throughout the study
Global evaluation of tolerability
Assessed by the subjects and investigator at the end of study

Full Information

First Posted
August 10, 2016
Last Updated
February 10, 2020
Sponsor
InQpharm Group
search

1. Study Identification

Unique Protocol Identification Number
NCT02871271
Brief Title
Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness
Official Title
Open-Label Pilot Study to Evaluate the Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Withdrawn
Why Stopped
Stopped product production
Study Start Date
November 2016 (Anticipated)
Primary Completion Date
March 2017 (Anticipated)
Study Completion Date
September 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
InQpharm Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the tolerability and benefit of IQP-AS-121 on reducing fatigue and tiredness and to improve mental alertness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fatigue

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
IQP-AS-121
Arm Type
Experimental
Arm Description
To be taken once daily dosing of 1 tablet in the morning.
Intervention Type
Dietary Supplement
Intervention Name(s)
IQP-AS-121
Primary Outcome Measure Information:
Title
Change in VAS-F parameter
Description
Compared between timepoints week 6 versus baseline - To assess fatigue and energy with 18 items which possesses two subscales: fatigue (13 items) and energy (5 items).
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Change in Bond & Lader VAS parameter
Description
Compared between timepoints week 6 versus baseline - To assess alertness, contentedness and calmness
Time Frame
6 weeks
Title
Change in Number Connection Test
Description
Compared between timepoints week 6 versus baseline - To assess visuo-spatial orientation and cognitive processing speed.
Time Frame
6 weeks
Title
Change in FAIR-2
Description
Compared between timepoints week 6 versus baseline - To measure attention as an ability to concentrate
Time Frame
6 weeks
Title
Change in SF-12 parameter
Description
Compared between timepoints week 6 versus baseline - To measure the overall health status of a subject
Time Frame
6 weeks
Title
Change in PSQ20 parameter
Description
Compared between timepoints week 6 versus baseline - Contained 30 items as an instrument to assess subjectively experienced stress
Time Frame
6 weeks
Title
Change in POMS-35 parameters
Description
Compared between timepoints week 6 versus baseline - The POMS-65 comprises 65 adjectives, separated into 6 subscales: 1) depression-dejection, 2) tension-anxiety, 3) anger-hostility, 4) confusion bewilderment, 5) fatigue-inertia and 6) vigour-activity.
Time Frame
6 weeks
Title
Global evaluation of benefit
Description
Assessed by the subjects and investigator at the end of study - To evaluate benefit of IP
Time Frame
6 weeks
Title
Adverse events
Description
Assessed throughout the study
Time Frame
6 weeks
Title
Global evaluation of tolerability
Description
Assessed by the subjects and investigator at the end of study
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Caucasian males and females, 21-55 years of age Body mass index (BMI) 18.5-29.9 kg/m2 Generally in good health without clinically significant findings at screening No chronic fatigue syndrome according to the Fukuda Centres for Disease Control and Prevention (CDC) criteria at screening Subjective feeling of chronic stress and tiredness for 3-12 last months prior to screening Screening Scale of Chronic Stress (SSCS) score >18 Fatigue Severity Scale score >4 ≤ 3 cups/portions of coffee and/or caffeine-containing food/beverages per day in the 3 last months prior to screening and during the study Regular stable continuous level of daily activities Regular sleep-wake cycle Normal dietary habits according to investigator's judgement ≤ moderate level of physical exercise Readiness to comply with study procedures, in particular: Consumption of the IP during the treatment period Filling in all questionnaires Keep habitual diet and level of physical exercise No change in smoking habits during the study Women of child-bearing potential only: negative pregnancy testing (ß-HCG in urine at screening) commitment to use reliable contraception methods during the entire study Participation is based upon written informed consent form (ICF) by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study. Exclusion Criteria: Known sensitivity to any components of the IP Any medical condition associated with tiredness (e.g. iron deficiency, hypotension etc.) History and/or presence of clinically significant disease, which per investigator's judgement could interfere with the results of the study or the safety of the subject: Psychiatric diseases, e.g. depression, schizophrenia Eating disorders such as anorexia Untreated or non-stabilized metabolic diseases, e.g. diabetes mellitus Untreated or non-stabilized thyroid disorder Untreated or non-stabilized hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg) Significant gastrointestinal diseases Insomnia Known bleeding disorders such as haemophilia Any other known significant or serious condition / disease that renders subjects ineligible (e.g. history of malignancy within the past 5 years prior to screening, any clinically significant cardiovascular, renal, liver disease etc.) Use of medication which in the investigator's judgement could interfere with the results of the study (e.g. psychoactive medication, statins, proton pump inhibitors, blood-pressure medications, antihistamines, antibiotics, diuretics) within the last 4 weeks prior to screening and during the study Consumption of vitamins, nutritional supplements, supplementary balanced diet, mineral products which in the investigator's judgement could interfere with the results of the study within last 4 weeks prior to screening and during the study Consumption of adaptogens (e.g. ginseng or Schisandra) or St. John's Wort within last 4 weeks prior to screening and during the study Consumption of energy drinks during the study Start of use of contraception medication during the last 3 months prior to screening and during the study Use of anticoagulants such as warfarin Clinically significant deviation of laboratory parameters and/or deviations > 2 x ULN (upper limit of normal) at screening Recent or current significant stressors (e.g. active grieving) Chronic pain Chronic sleep deficiency (< 5 hours/night) Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits) Drug abuse Participation in another study during the last 30 days prior to screening Women of child-bearing potential: pregnant or breastfeeding Any situation expected during the study causing acute high level of stress Any other reason deemed suitable for exclusion as per investigator's judgment, e.g. insufficient compliance with study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ralf Uebelhack,, MD, PhD
Organizational Affiliation
analyze & realize GmbH
Official's Role
Principal Investigator
Facility Information:
Facility Name
analyze & realize GmbH
City
Berlin
ZIP/Postal Code
10369
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness

We'll reach out to this number within 24 hrs